A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...

DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together ...

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for ...

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...